Marinus Pharmaceuticals Shares Plunge as Phase 3 Trial of Ganaxolone Fails to Meet Goal; Plans to Cut Costs, Explore Alternatives
Marinus Pharmaceuticals (MRNS) shares plunged nearly 82% in recent Thursday trading after the company said its phase 3 trial of oral ganaxolone failed to meet its main goal and announced plans to reduce costs and explore alternatives for the business.
Marinus was studying the drug as a treatment for seizures associated with tuberous sclerosis complex in children and adults. The trial failed to achieve "statistical significance" on its primary endpoint of percent change in 28-day frequency of tuberous sclerosis complex-associated seizures, the drugmaker said.
Marinus said it would no longer be developing ganaxolone and would take steps to save costs, including a workforce reduction.
The company also said it has hired Barclays to assist in reviewing its strategic alternatives.
Price: 0.31, Change: -1.38, Percent Change: -81.89
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
No relevant data is available